ArticleAddictive behaviors reports2022
Lifetime use of non-nicotine drugs in electronic cigarette devices among a sample of individuals in substance use disorder treatment.
Article in Addictive behaviors reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Persistent effects of repeated adolescent and adult heroin vapor inhalation in female Wistar rats.Psychopharmacology · 2026Article
- Drug-laced vaping-implications and emerging perioperative challenges for the anesthesiologist: a narrative review.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026Review
- Reactivity to electronic nicotine delivery system (ENDS) cues in adults who smoke cigarettes and vape cannabis.Addictive behaviors · 2026Article
- Prevalence and reasons for electronic nicotine delivery systems modifications among U.S. youth, young adult, and adult users.Scientific reports · 2025Article
- E-cigarette use among a national sample of adults receiving substance use treatment in the United States.Addictive behaviors · 2025Article
- Dual-Vaping of Nicotine and Cannabis Among Adults Who Currently Use Tobacco Products in Five New England States.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Article
- Survey of U.S. Residents and Their Usage of Electronic Cigarettes with Drugs Other Than Nicotine.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Limited data are available on other substance use in e-cigarettes (OSUE). The aim of this research was to determine the prevalence and predictors of OSUE among a sample of individuals in substance use disorder (SUD) treatment. Methods: In 2019, we surveyed 553 individuals from 18 residential SUD treatment programs in California, USA. Individuals reporting any lifetime use of an e-cigarette containing nicotine (n = 279) were asked about ever use of drugs other than nicotine in their e-cigarette. Those who reported use of non-nicotine drugs in their e-cigarette also reported what psychoactive drugs were used. Results: Among all the participants, 25 % (n = 139) . reported ever engaging in OSUE. The most common drugs used in vaping devices were marijuana/THC/hash, (70.5 %, n = 98) and amphetamines/methamphetamine (51.1 %, n = 71). Among those who had engaged in OSUE, 44.6 % (n = 62) had vaped drugs for which they sought treatment. Older persons (OR = 0.93, CI 0.91, 0.95) and African Americans (OR = 0.48, CI 0.24, 0.94) were less likely to have ever engaged in OSUE, while persons in treatment for opioid use were more likely (OR = 1.71, CI 1.08, 2.71). Conclusion: Among a sample of clients in SUD treatment, about 25% had ever engaged in OSUE, with THC/marijuana and amphetamines most commonly reported. Further research is needed to evaluate the OSUE to understand the reasons for use and implications among persons enrolled in SUD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.